Basic Information
Gavreto
Regulatory Information
EMEA/H/C/005413
Withdrawn
November 18, 2021
September 16, 2021
8
July 22, 2024
Company Information
Netherlands
Gustav Mahlerplein 2 1082MA Amsterdam
Blueprint Medicines (Netherlands) BV
Drug Classification
Conditional Approval
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Gavreto is indicated as monotherapy for the treatment of adult patients with rearranged during transfection (RET) fusion-positive advanced non-small cell lung cancer (NSCLC) not previously treated with a RET inhibitor.
Overview Summary
Gavreto is a cancer medicine for treating adults with advanced non-small cell lung cancer caused by changes in a gene called RET (known as RET fusion-positive NSCLC) and who have not been treated with a RET inhibitor. Gavreto contains the active substance pralsetinib.